Showing 1299 results
- Clinical Trials /
- Clinical Trials /
- Clinical Trials /
- Clinical Trials /
- Story /
Novartis researchers are learning how a novel approach to immunotherapy could help treat cancer.
- Media Release /Phase III PARADIGMS study in pediatric MS met its primary endpoint, showing a significant reduction in relapses occur with fingolimod versus interferon beta-1a There is a significant unmet…
- Media Release /In a Phase III clinical study, Zykadia® extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global…
- Media Release /Study in patients with advanced nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin met primary endpoint[1] Full results will be submitted for presentation at…
- Key Release /Cosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira®*[1] Statistically…
- Media Release /Primary analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate with one-time Kymriah infusion1Robust response observed in heavily pretreated patients in…
Pagination
- ‹ Previous page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- …
- 130
- › Next page